Stock Taper 
Bioventus Inc. develops and commercializes medical devices and treatments that promote natural healing, including pain management, surgical solutions, and restorative therapies for orthopedic and wound care globally.
Bioventus's ultrasonic bone cutting system enables precise, safe minimally invasive spine surgery, forming a key part of their Surgical Solutions portfolio for the growing minimally invasive spine market.
Bioventus announced its third-quarter 2025 financial results on November 4, 2025, reporting an adjusted earnings per share of $0.15, a 200% increase from the prior-year period and significantly beating analyst expectations. This strong performance, which also saw an 8% organic revenue growth, led to a significant positive reaction from investors and reaffirmed the company's full-year guidance.
Bioventus received FDA 510(k) clearance for two next-generation Peripheral Nerve Stimulation (PNS) products, TalisMann™ and StimTrial™, for chronic pain management. This strategic move marks the company's entry into the fast-growing PNS market, which is a key part of its strategy to shift its portfolio towards higher-growth end markets with differentiated technology.
RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Analyst Ratings This is a summary of recent recommendations
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
 SNN | $26.91 | COMPARE |
 BFLY | $8.77 | COMPARE |
 IART | $13.31 | COMPARE |
 CBLL | $24.57 | COMPARE |
 VREX | $18.49 | COMPARE |
 CTKB | $5.58 | COMPARE |
 MDXG | $4.60 | COMPARE |
 KIDS | $22.82 | COMPARE |
